John B. Henneman III - Jun 30, 2021 Form 4 Insider Report for Aprea Therapeutics, Inc. (APRE)

Role
Director
Signature
/s/ Scott M. Coiante, attorney-in-fact
Stock symbol
APRE
Transactions as of
Jun 30, 2021
Transactions value $
$0
Form type
4
Date filed
7/1/2021, 07:09 PM
Previous filing
Jun 21, 2021
Next filing
Jul 1, 2021

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction APRE Common Stock Award $0 +4.61K +92.2% $0.00 9.61K Jun 30, 2021 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction APRE Stock Option (Right to Buy) Award $0 +22.8K $0.00 22.8K Jun 30, 2021 Common Stock 22.8K $4.88 Direct F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 These shares represent restricted stock units which were granted on June 30, 2021, and which will vest and be settled in common stock on June 30, 2022, subject to the reporting person's continued service on the Issuer's board of directors through and including the applicable vesting date and subject to acceleration under certain conditions.
F2 The option vests in full on June 30, 2022, subject to the reporting person's continued service on the Issuer's board of directors through and including the applicable vesting date and subject to acceleration under certain conditions.